Merck: applies to FDA for gefapixant approval
(CercleFinance.com) - Merck announced on Monday that it has filed a New Drug Application (NDA) with the US FDA for gefapixant, an oral investigational drug for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults.
"If approved by the FDA, gefapixant would be the first medicine approved specifically to help these patients, and we look forward to participating in the advisory committee meeting and working with the FDA as they review our application," said Dr. Roy Baynes, Medical Director at Merck Research Laboratories.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
"If approved by the FDA, gefapixant would be the first medicine approved specifically to help these patients, and we look forward to participating in the advisory committee meeting and working with the FDA as they review our application," said Dr. Roy Baynes, Medical Director at Merck Research Laboratories.
Copyright (c) 2021 CercleFinance.com. All rights reserved.